Cryogenic Biobanking Services in the US: Market Size, Businesses & Forecast 2026

The Cryogenic Biobanking Services industry in the United States comprises specialized repositories and establishments dedicated to the ultra-low temperature preservation and logistics of human biological specimens, including stem cells, tissues, blood, and organs. Driven by advancements in regenerative medicine and clinical research, the sector plays a critical role in supporting personalized therapeutics and multi-omics drug discovery. As of 2026, the industry is seeing heightened consolidation as corporate networks expand to meet rigorous federal storage compliance, exemplified by major government-funded programs such as the National Institutes of Health (NIH) 'All of Us' Research Program

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Cryogenic Biobanking Services in the US industry cover?

The industry encompasses facilities and commercial services focused on the collection, processing, cryogenic storage, and cold-chain distribution of biospecimens. These operations primarily rely on ultra-low temperature freezers and liquid nitrogen systems to maintain long-term cellular viability for medical research and therapeutic utilization. The scope extends across private cord blood banking, academic research repositories, and therapeutic cell banks.

• •Involves the structural preservation of human tissues, DNA, RNA, proteins, and fluid biospecimens at temperatures typically below -130 degrees Celsius.
• •Serves diverse end-users including clinical trial sponsors, biotechnology companies, academic universities, and individual healthcare consumers.
• •Excludes conventional short-term hospital blood banks focused primarily on immediate, non-cryogenic transfusion services.

Who operates in the industry and how is it structured?

The market structure is categorized by a mix of non-profit academic biobanks, government-operated research repositories, and private commercial ventures. While public and academic repositories house the largest sheer volume of diverse population disease samples, private entities heavily dominate commercial contract storage and private family cord blood banking. The structural shift leans toward unified national networks to standardize pre-analytical sample quality.

• •Academic and university-affiliated institutions historically maintain the largest share of physical infrastructure within the broader biorepository ecosystem.
• •Private commercial operations emphasize specialized high-throughput storage, regulatory-grade validation, and international cold-chain logistics services.
• •The National Institutes of Health (NIH) and the National Cancer Institute (NCI) fund extensive public biorepository operations across the United States.

What drives demand in the industry?

Primary demand is propelled by the rapid expansion of genomic medicine, multi-omics research, and the proliferation of clinical trials utilizing cell and gene therapies. The rising incidence of chronic diseases and cancer necessitates accessible, high-quality human tissue biospecimens to discover novel biomarkers and validate target therapies. Additionally, individual consumer demand for newborn stem cell and cord blood preservation remains a steady foundational component.

• •The expansion of population-scale genomics programs requires vast, highly standardized physical sample sets to feed artificial intelligence drug discovery models.
• •According to the National Cancer Institute (NCI) 2026 briefs, access to high-quality, uncompromised human biospecimens remains a critical bottleneck for advancing targeted oncology research.
• •Increased federal funding via the National Center for Advancing Translational Sciences (NCATS) directly drives institutional biorepository development.

Who are the notable companies in the industry?

The competitive landscape features a highly competitive mix of specialized cryogenic storage corporations, global life sciences conglomerates, and localized laboratory service providers. Market participants differentiate themselves through geographic facility distribution, emergency backup power infrastructure, and accredited biological data management systems. Consolidation is active as larger corporations acquire niche family banks and regional clinical networks.

• •Cryo-Cell International, Inc. operates as a prominent public commercial entity focused directly on umbilical cord blood and tissue cryogenic biobanking.
• •Thermo Fisher Scientific Inc. serves as a massive corporate supplier and service provider managing outsourced ultra-low temperature biorepository networks.
• •Charles River Laboratories International, Inc. and Laboratory Corporation of America Holdings (Labcorp) engage in specialized biological specimen storage and clinical processing operations.
• •Azenta, Inc. (formerly Brooks Automation) functions as a major dedicated player providing automated cryogenic storage solutions and sample repository services.

What are the recent trends and outlook?

Recent developments are heavily focused on the integration of virtual biobanking and automated robotic retrieval systems to minimize transient warming events during sample handling. Virtual biobanking connects physical specimens with electronic health records (EHR) and multi-omic datasets, maximizing the utility of stored samples without premature thawing. The forward outlook highlights a continuous shift toward automated liquid nitrogen storage units that eliminate manual human intervention.

• •Automation systems increasingly deploy robotic arms inside ultra-low environments to maintain strict temperature compliance during selection.
• •Data-driven virtual biobanking networks allow global researchers to screen physical inventory parameters online prior to ordering shipment.
• •Sustainability measures are driving the adoption of energy-efficient Stirling ultra-low freezers to reduce the carbon footprint of massive compressor farms.

How is the industry regulated?

Operations are governed by a complex matrix of federal oversight, institutional frameworks, and voluntary accreditation bodies to guarantee donor privacy and specimen integrity. Establishments handling human cells or tissues intended for transplantation are subject to strict registration and regulations enforced by the U.S. Food and Drug Administration (FDA). Researchers utilizing these repositories must maintain rigorous protocols regarding donor informed consent and personal data protection.

• •Establishments are regulated under FDA 21 CFR Part 1271 guidelines covering Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).
• •The National Cancer Institute (NCI) publishes the 'NCI Best Practices for Biospecimen Resources' to standardize collection, processing, and retrieval operations.
• •Research programs utilizing biobank specimens require oversight from an Institutional Review Board (IRB) to safeguard Personal Identifying Information (PII) under federal privacy laws.

Government, statistical and trade sources used for this Claight analysis.

• National Institutes of Health (NIH) 2026 ·
• National Cancer Institute (NCI) Biospecimen Resources 2026 ·
• U.S. Food and Drug Administration (FDA) HCT/P Regulations ·
• U.S. Census Bureau NAICS 2022 Manual ·
• Securities and Exchange Commission (SEC) Corporate Filings 2026